A postponement, not a breakthrough
Investors in Feedback plc (LSE/AIM: FDBK) began 2026 hoping for confirmation that its Bleepa clinical-communications platform had won a place in a nationwide NHS rollout. What arrived instead, in a Regulatory News Service announcement on 20 April 2026, was a delay. The central NHS decision Feedback had been awaiting has been postponed by an estimated six to nine months, pushing any verdict into the 2026/27 NHS financial year. The market reaction was blunt: the shares fell around 20% on the day, from roughly 14.4p to 11.5p (source: AJ Bell / Alliance News, 20 April 2026).
That single announcement reframes the entire investment case. Rather than a company on the cusp of a "breakout," Feedback is a small, loss-making software business managing a finite cash runway while it waits on a decision outside its control. This article assesses what is actually verifiable, and weighs the case both ways.
Company overview and principal operations
Feedback plc is a UK-listed digital-health company. Its lead product, Bleepa, is a clinical-grade communications and medical-imaging platform that lets clinicians view diagnostic images and coordinate patient care across care settings on secure devices. A companion offering, CareLocker, provides the underlying data-hosting architecture intended to sit patient records at the centre of a care pathway.
The commercial thesis is that Bleepa can digitise NHS referral and diagnostic pathways, cutting delays and unnecessary appointments. In the six months to 30 November 2025, Bleepa accounted for 89% of group sales (source: half-year report, 17 February 2026), so the platform is effectively the whole equity story. The business is led by chief executive Dr Tom Oakley, and the company confirmed a CFO board appointment on 16 February 2026.
The latest catalyst, examined
The 20 April 2026 "NHS Progress and Business Update" is the most material recent event. Its core message: a national business case for Bleepa — submitted under the NHS Spending Review process — has not been rejected, but the decision timetable has slipped by roughly six to nine months. Management's stated hope is that the opportunity will realign with new frontline-digitisation funding expected during the 2026/27 NHS financial year.
Alongside the delay, Feedback reported a mix of contract news. Queen Victoria Hospital NHS Foundation Trust extended its Bleepa deployment for nine months to December 2026, at an annualised value of £495,000, with cancer-pathway support. The Northern Care Alliance NHS Foundation Trust renewed its contract. Less positively, a photocapture contract with Royal Berkshire NHS Foundation Trust was not renewed and expired at the end of March 2026 — Feedback framed this as a deliberate decision to concentrate resources on higher-value pathway work and preserve capital.
CEO Dr Tom Oakley struck an optimistic tone: "Whilst we await the outcomes of central NHS decisions, we will focus on expanding the programme at QVH and other pathway opportunities" (source: Alliance News, 20 April 2026). That is a reasonable holding strategy — but it is a holding strategy, not the transformational national win the earlier narrative implied.
Latest financial performance
The numbers underline how early-stage and cash-consumptive this business remains. For the half-year to 30 November 2025 (reported 17 February 2026), Feedback posted revenue of £0.41m — broadly stable year on year — while its adjusted EBITDA loss widened to £1.61m, which management attributed to increased hiring and investment in cloud technology.
The full-year picture for the year ended 31 May 2025 (reported 17 September 2025) was weaker still. Revenue fell about 25% to £0.89m, which the company put down to non-recurring contributions in the prior year and delayed NHS wins. The operating loss was £4.21m and the loss after tax was £7.32m — a figure inflated by a £3.19m impairment of intangible assets, booked on conservative assumptions amid NHS uncertainty. Notably, one customer represented 55% of group revenue that year, a stark concentration risk.
Put plainly: revenue is tiny, losses dwarf sales, and the top line is lumpy and highly concentrated. This is a pre-scale business whose value rests almost entirely on future adoption rather than current trading.
Balance sheet, liquidity and funding
Cash is the decisive variable. Feedback ended FY2025 (31 May 2025) with £5.95m of cash, helped by a £6.1m fundraise completed in November 2024. By 30 November 2025 that balance had fallen to £3.82m. The company states its funding runway extends "into mid-2027."
The encouraging feature is that Feedback is debt-free — there is no borrowing overhang. The uncomfortable feature is arithmetic: a roughly £1.6m half-year cash outflow against £3.82m of cash implies limited headroom if the national decision continues to slip and revenue does not step up. A runway "into mid-2027" is not the same as a runway through it. Should the awaited NHS verdict arrive late or unfavourably, a further equity raise — and consequent dilution for existing holders — becomes a realistic possibility. That risk is analysis, but it follows directly from the disclosed cash figures.
Operational progress and strategic outlook
It would be wrong to paint the period as purely negative. Feedback has completed integrations of Bleepa with core NHS systems, including the NHS e-Referral Service, which is a genuine technical prerequisite for pathway-scale adoption. It was selected to take part in national simulations of the government's new Neighbourhood Health Service model, and it has paused its Indian operations to focus resources on the UK. The company has also referenced late-stage discussions with consulting, cloud and technology partners.
The strategy is coherent: prove the model trust-by-trust, embed deeply into NHS plumbing, and be positioned when national digitisation funding flows. The problem is timing. Each of these steps is a leading indicator, not a revenue event, and the market has repriced the shares to reflect that the decisive commercial catalyst has moved further away.
Industry and competitive context
The macro backdrop is genuinely supportive in the long run. The NHS is under sustained pressure to cut waiting lists and elective backlogs, and successive policy statements have emphasised digitisation of diagnostics and referrals. That is the tailwind Feedback is built to catch.
But the same environment creates the delays now hurting the company. NHS procurement is slow, budget cycles are uncertain, and central decisions can be deferred for reasons entirely unrelated to a supplier's product quality — which is precisely what appears to have happened here. Feedback also competes for attention and budget against far larger electronic-patient-record and imaging incumbents. Being small and nimble is an advantage in pilots; it is a disadvantage when a cash-constrained micro-cap must outlast a bureaucratic timetable.
Potential growth catalysts
The credible, evidence-based catalysts are: a positive outcome to the national Bleepa business case, now expected to align with 2026/27 NHS funding; conversion of existing trust relationships — QVH, Northern Care Alliance and others — into larger, longer, recurring contracts; tangible commercial partnerships with the cloud/consulting firms management has referenced; and any role emerging from the Neighbourhood Health Service simulations. Each is plausible. None is confirmed, and the recent record argues for caution on timing.
Principal risks and warning signs
The risks are substantial and should be weighted at least as heavily as the upside. Cash runway extends only into mid-2027, raising the prospect of dilutive fundraising. Revenue is minuscule and, historically, highly concentrated in a single customer. Losses remain large relative to sales. The share price has fallen sharply — from a 52-week high of 14.75p (25 February 2026) to a 52-week low of 6.50p (3 July 2026), trading around 6–7p in late July 2026 for a market capitalisation of roughly £2.7–3.0m (source: Stockopedia / LSE.co.uk quotes, 28 July 2026). Above all, the single most important commercial decision sits with the NHS, not the company, and has already slipped once.
Balanced investor considerations
For the patient, risk-tolerant investor, Feedback offers optionality: a debt-free platform business, real NHS integrations, and a genuine — if delayed — national opportunity, all at a depressed valuation. For the risk-averse, the combination of a finite cash runway, widening losses, customer concentration and a decision timetable outside management's control is a serious deterrent. This is a binary, catalyst-dependent micro-cap, not a steadily compounding software name.
Conclusion
The evidence does not support the idea of an imminent "breakout." As of 28 July 2026, the verifiable position is that Feedback's hoped-for national NHS scale-up decision has been deferred into the 2026/27 financial year, the shares sit near 52-week lows, and cash funds operations only into mid-2027. The long-term thesis — digitising NHS pathways with Bleepa — remains intact and technically credible. But the near-term reality is one of waiting, cash discipline and elevated dilution risk. Whether that patience is rewarded depends on a decision Feedback cannot make itself.
Key Takeaways
- Feedback's awaited central NHS decision on a national Bleepa rollout was delayed by an estimated six to nine months (RNS, 20 April 2026), sending shares down about 20% on the day.
- Financials remain early-stage: H1 to 30 Nov 2025 revenue £0.41m with a widened £1.61m adjusted EBITDA loss; FY2025 revenue £0.89m and £7.32m loss after tax (incl. £3.19m impairment).
- Cash of £3.82m at 30 Nov 2025 funds operations only "into mid-2027"; the company is debt-free but faces realistic dilution risk if the NHS verdict slips further.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...